Should Dengue Vaccination be Prioritized in Individuals with Diabetes?

Résumé fourni par la source

Abstract Type 2 diabetes (T2D) is a rapidly expanding global health challenge that heightens vulnerability to infections, including dengue, the most widespread mosquito-borne viral disease worldwide. Emerging evidence indicates that individuals with T2D are at increased risk of severe dengue manifestations, such as dengue hemorrhagic fever and dengue shock syndrome, a vulnerability likely driven by diabetes-associated immune dysregulation, endothelial dysfunction, metabolic derangements, and chronic low-grade inflammation, especially in the setting of poor glycemic control. This review summarizes current epidemiological evidence linking T2D to dengue severity and examines the key immunopathogenic mechanisms underlying this association. It also reviews the evolution of dengue vaccines, noting that previous candidate vaccines were limited by safety and implementation concerns, and provides an overview of contemporary vaccine platforms while highlighting the scarcity of data specific to people with diabetes. Importantly, we identify gaps in existing dengue guidelines regarding diabetes-focused prevention and management. Finally, we outline priorities for future research and discuss the potential role of dengue vaccination within diabetes care pathways, while emphasizing the need for diabetes-specific clinical trials, safety evaluations, and health-economic studies before vaccination prioritization can be recommended.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.